FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982984014> ?p ?o ?g. }

• W2982984014 endingPage "4509" @default.
• W2982984014 startingPage "4509" @default.
• W2982984014 abstract "Introduction: Allogeneic haematopoietic cell transplant ( allo-HCT) is an effective consolidative treatment for patients with certain haematological malignancies and gives the best outcome when done in remission. However patients with refractory acute myeloid leukemia (AML) or some myeloproliferative neoplasia (MPN) and myelodysplastic syndrome (MDS) deemed unable to achieve remission with standard induction are often excluded from allo HCT with conventional conditioning regimen as pre-transplant remission could not be achieved. Recently, a sequential transplant approach, as developed by the Munich group, comprising of intensive cytoreductive chemotherapy FLAMSA (Fludarabine/Amsacrine/Cytarabine) to decrease leukemia cell burden shortly prior to conditioning regimen, has been successfully used for high-risk (HR) AML/MDS with promising results. Methods: We studied 48 patients (median age 53 years, range 26 - 68) with high risk AML (n=38), as defined by refractory, relapsed disease, secondary leukemia, complete remission with adverse-risk cytogenetics according to ELN criteria, or high/very risk refined Disease Risk Index (DRI), MPN(n=2) and HR MDS (n=8) according to IPSS-R, undergoing allo-HCT using the sequential transplant approach in 2 transplant centers in Singapore between January 2009 and October 2018. The sequential transplant approach combined a cytoreductive chemotherapy, which consisted of either FLAMSA (n=17), FLAG +/- Ida (fludarabine/Cytarabine/Granulocyte Colony Stimulating factor (GCSF) +/- Idarubicin] (n=23), or CLAG (Clofarabine / Cytarabine / GCSF) (n=8), followed by reduced intensity (RIC) (N=43) or myeloablative (MAC) (N=5) conditioning regimen. All patients received peripheral blood stem cell from matched related donors (N=27), matched unrelated donors (N=14), or mismatched unrelated donors (N=7). Post-grafting immunosuppression consisted of calcineurin inhibitor and mycophenolate mofetil in all patients. Thymoglobuline was added for GVHD prophylaxis for unrelated donor transplant. Results: The median time to neutrophil > 1000/μL was 10 days (range, 9-25). With a median follow-up of 48 months (range, 9 to 111 months), the Kaplan-Meier estimate of overall survival (OS) and leukemia-free (LFS) at 5 years were 48 % (95% CI, 33-62), 45% (95% CI, 30-58), respectively. At 2 years cumulative incidence of relapse and non-relapse mortality (NRM) were 51% (95% CI, 33-67) and 15% (95% CI, 7-27), respectively. Patients receiving FLAG or CLAG based sequential regimen showed, lower cumulative incidence of NRM (2-year CI NRM: 7% vs 40%; p=0.037), and similar relapse (2 year CI relapse: 49% vs 53%; p=0.63) as compared to patients given FLAMSA-based sequential regimen, resulting in a trend towards more favourable OS (5 year OS: 53% vs 40%; p=0.33) and LFS (5 year LFS: 54% vs 35%; p=0.23). In multivariable analysis, only refined DRI showed significant impact on OS (p=0.04), but has no significant impact on LFS, NRM and relapse. The 5-year OS for patients with intermediate/high risk and very high risk DRI were 60% and 24%, respectively (p=0.024), and the corresponding 5-year LFS were 57%, and 27% (p=0.065), respectively (Figure 1 & Figure 2). The intensity of conditioning regimen did not significantly impact on OS, LFS, relapse and NRM. Conclusions: Sequential transplant conditioning with FLAMSA, FLAG or CLAG followed by allo-HCT is an effective strategy in overcoming the dismal prognosis of high risk AML, MDS and MPN, and enabling favourable long-term disease free survival. More studies on effective strategies such as post-transplant maintenance therapy with prophylactic donor lymphocyte infusion, are needed to further eliminate the risk of relapse, without increasing risk of treatment related toxicity. Disclosures No relevant conflicts of interest to declare." @default.
• W2982984014 created "2019-11-22" @default.
• W2982984014 creator A5009767871 @default.
• W2982984014 creator A5013342531 @default.
• W2982984014 creator A5017656417 @default.
• W2982984014 creator A5023414791 @default.
• W2982984014 creator A5040598983 @default.
• W2982984014 creator A5080466962 @default.
• W2982984014 creator A5080656059 @default.
• W2982984014 creator A5090626293 @default.
• W2982984014 creator A5091237771 @default.
• W2982984014 creator A5091877874 @default.
• W2982984014 date "2019-11-13" @default.
• W2982984014 modified "2023-09-30" @default.
• W2982984014 title "High Dose Flamsa, CLAG or FLAG-Based Sequential Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasia Patients: A Multicenter Study in Singapore" @default.
• W2982984014 doi "https://doi.org/10.1182/blood-2019-125246" @default.
• W2982984014 hasPublicationYear "2019" @default.
• W2982984014 type Work @default.
• W2982984014 sameAs 2982984014 @default.
• W2982984014 citedByCount "0" @default.
• W2982984014 crossrefType "journal-article" @default.
• W2982984014 hasAuthorship W2982984014A5009767871 @default.
• W2982984014 hasAuthorship W2982984014A5013342531 @default.
• W2982984014 hasAuthorship W2982984014A5017656417 @default.
• W2982984014 hasAuthorship W2982984014A5023414791 @default.
• W2982984014 hasAuthorship W2982984014A5040598983 @default.
• W2982984014 hasAuthorship W2982984014A5080466962 @default.
• W2982984014 hasAuthorship W2982984014A5080656059 @default.
• W2982984014 hasAuthorship W2982984014A5090626293 @default.
• W2982984014 hasAuthorship W2982984014A5091237771 @default.
• W2982984014 hasAuthorship W2982984014A5091877874 @default.
• W2982984014 hasConcept C126322002 @default.
• W2982984014 hasConcept C136119220 @default.
• W2982984014 hasConcept C141071460 @default.
• W2982984014 hasConcept C143998085 @default.
• W2982984014 hasConcept C202444582 @default.
• W2982984014 hasConcept C2776694085 @default.
• W2982984014 hasConcept C2776730729 @default.
• W2982984014 hasConcept C2776755627 @default.
• W2982984014 hasConcept C2778041864 @default.
• W2982984014 hasConcept C2778336483 @default.
• W2982984014 hasConcept C2778461978 @default.
• W2982984014 hasConcept C2778729363 @default.
• W2982984014 hasConcept C2779263901 @default.
• W2982984014 hasConcept C2781413609 @default.
• W2982984014 hasConcept C2911091166 @default.
• W2982984014 hasConcept C33923547 @default.
• W2982984014 hasConcept C71924100 @default.
• W2982984014 hasConcept C90924648 @default.
• W2982984014 hasConceptScore W2982984014C126322002 @default.
• W2982984014 hasConceptScore W2982984014C136119220 @default.
• W2982984014 hasConceptScore W2982984014C141071460 @default.
• W2982984014 hasConceptScore W2982984014C143998085 @default.
• W2982984014 hasConceptScore W2982984014C202444582 @default.
• W2982984014 hasConceptScore W2982984014C2776694085 @default.
• W2982984014 hasConceptScore W2982984014C2776730729 @default.
• W2982984014 hasConceptScore W2982984014C2776755627 @default.
• W2982984014 hasConceptScore W2982984014C2778041864 @default.
• W2982984014 hasConceptScore W2982984014C2778336483 @default.
• W2982984014 hasConceptScore W2982984014C2778461978 @default.
• W2982984014 hasConceptScore W2982984014C2778729363 @default.
• W2982984014 hasConceptScore W2982984014C2779263901 @default.
• W2982984014 hasConceptScore W2982984014C2781413609 @default.
• W2982984014 hasConceptScore W2982984014C2911091166 @default.
• W2982984014 hasConceptScore W2982984014C33923547 @default.
• W2982984014 hasConceptScore W2982984014C71924100 @default.
• W2982984014 hasConceptScore W2982984014C90924648 @default.
• W2982984014 hasIssue "Supplement_1" @default.
• W2982984014 hasLocation W29829840141 @default.
• W2982984014 hasOpenAccess W2982984014 @default.
• W2982984014 hasPrimaryLocation W29829840141 @default.
• W2982984014 hasRelatedWork W1148551369 @default.
• W2982984014 hasRelatedWork W2038117849 @default.
• W2982984014 hasRelatedWork W2353568056 @default.
• W2982984014 hasRelatedWork W2368167615 @default.
• W2982984014 hasRelatedWork W2370782339 @default.
• W2982984014 hasRelatedWork W2373928853 @default.
• W2982984014 hasRelatedWork W2382214347 @default.
• W2982984014 hasRelatedWork W2383638159 @default.
• W2982984014 hasRelatedWork W2512151351 @default.
• W2982984014 hasRelatedWork W3032260332 @default.
• W2982984014 hasVolume "134" @default.
• W2982984014 isParatext "false" @default.
• W2982984014 isRetracted "false" @default.
• W2982984014 magId "2982984014" @default.
• W2982984014 workType "article" @default.